David Thompson, M.A., M.S., Ph.D.
Member of Scientific Advisory Board, Senior Advisor to Inozyme
David Thompson is a senior adviser to Inozyme and served as Inozyme’s Senior Vice President and Chief Scientific Officer from 2018-2020. He has more than 30 years of experience designing and leading research and development programs focused on bone disorders and phosphate regulation. In his time with Inozyme, Dr. Thompson was responsible for scientific research as the company builds its proprietary pipeline of investigational therapies, beginning with INZ-701.
Prior to joining Inozyme Pharma, he was a founder and president of Azure Biotech, where he was responsible for the development of a novel formulation of lasofoxifene, a non-steroidal selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the treatment of vaginal atrophy.
Previously, Dr. Thompson held executive positions in clinical research and drug development in multiple biopharma companies, including Alexion Pharmaceuticals, where he led the clinical development of asfotase alfa for the treatment of hypophosphatasia; and Pfizer, where he oversaw the osteoporosis research and frailty discovery groups. While at Merck Research Labs, he conducted preclinical work and participated in the early clinical development of alendronate for the treatment of osteoporosis.
Dr. Thompson received his M.A. from the University of Montana and both his M.S. and Ph.D. from the University of Connecticut.